Global 50 law firm Goodwin has been named the 2017 U.S. News & World Report - Best Lawyers’ “Law Firm of the Year” for Biotechnology Law for the fourth time in the past five years. Goodwin is one of just three firms to be honored with the recognition since the inception of the rankings in 2010.
Each year U.S. News & World Report - Best Lawyers recognizes one law firm per legal practice area based on the firm’s performance in client surveys, feedback from peer attorneys at other firms and information provided to the publication as part of its annual law firm ranking survey. For the 2017 edition of “Best Law Firms,” 13,044 U.S. firms, in 186 regional areas, were eligible for recognition.
“We are thrilled to once again be selected by our clients and peers for this honor,” said Mitchell Bloom, Chair of Goodwin’s Life Sciences Practice. “Goodwin is committed to providing our industry leading clients with best-in-class life cycle support. This recognition is reflective of the depth and breadth of our robust team which we continue to strengthen with the addition of seasoned life sciences lawyers across our offices.”
Goodwin’s Life Sciences Practice is among the leading practices in the United States, with more than 100 experienced life sciences lawyers. Its full-service team serves all legal needs of life sciences clients from corporate and partnering to intellectual property, regulatory and litigation. Clients include more than 400 private and public life sciences companies and their investors, from start-ups and Fortune 100 corporations to venture capital funds and investment banks. In 2016, Goodwin was named the Venture Capital Firm of the Year and the Hatch-Waxman Firm of the Year by LMG Life Sciences.
The firm’s Life Sciences practiced has advised on a number of landmark transactions in the past year including:
- Carrick Therapeutics $95 million financing
- Moderna's $474 million equity financing
- Galapagos NV’s global partnership with Gilead Sciences
- Stemcentrix $5.8 billion sale to AbbVie